Avalo Therapeutics (AVTX) Preferred Stock Liabilities (2014 - 2024)
Avalo Therapeutics' (AVTX) quarterly Preferred Stock Liabilities came in at $1.7 million in Q3 2024, down 85.53% on a QoQ basis from $11.5 million in Q2 2024.
Powered by 
Analysis
Avalo Therapeutics (AVTX) Preferred Stock Liabilities (2014 - 2024) Analysis & Trends
Avalo Therapeutics (AVTX) has 3 years of Preferred Stock Liabilities data on file, last reported at $1.7 million in Q3 2024.
- Quarterly Preferred Stock Liabilities changed N/A year-over-year to $1.7 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $1.7 million (changed N/A YoY) and the FY2014 annual result came in at $28.3 million, up 42.75% from the prior year.
- Preferred Stock Liabilities fell to $1.7 million in Q3 2024, from $11.5 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $11.5 million in Q1 2024 to a low of $1.7 million in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Avalo Therapeutics | 843.26 Mn | 843.26 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2024 | 1.66 Mn |
| Jun 30, 2024 | 11.46 Mn |
| Mar 31, 2024 | 11.46 Mn |
| Sep 30, 2015 | 28.35 Mn |
| Dec 31, 2014 | 28.35 Mn |